ARWR Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 46% planned / 54% discretionary
Largest single sale: $6.9M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| PERRY MICHAEL S | Director | Sell | 11,600 | $87.30 | $1.0M | 111,459 −9.4% of holding | |
| OLUKOTUN ADEOYE Y | Director | Sell | 2,000 | $86.96 | $173.9K | 31,600 −6% of holding | |
| Lu Hongbo | Director | Sell 10b5-1 | 2,970 | $76.88 | $228.3K | 52,012 −5.4% of holding | |
| Hamilton James C | Chief Medical Officer | Sell 10b5-1 | 10,000 | $75.00 | $750.0K | 226,958 −4.2% of holding | |
| Apel Daniel Joseph 3 fills | Chief Financial Officer | Sell 10b5-1 | 13,095 | $71.35 | $934.3K | 172,792 −7% of holding | |
| Hamilton James C | Chief Medical Officer | Sell 10b5-1 | 10,000 | $64.19 | $641.9K | 236,958 −4% of holding | |
| O'Brien Patrick 12 fills | COO | Sell 10b5-1 | 49,493 | $63.11 | $3.1M | 520,033 −8.7% of holding | |
| Hamilton James C 7 fills | Chief Medical Officer | Sell 10b5-1 | 40,164 | $63.11 | $2.5M | 207,497 −16.2% of holding | |
| Anzalone Christopher Richard 2 fills | Chief Executive Officer | Sell 10b5-1 | 13,187 | $66.10 | $871.7K | 3,798,510 −0.3% of holding | |
| Anzalone Christopher Richard 2 fills | Chief Executive Officer | Sell 10b5-1 | 51,726 | $69.13 | $3.6M | 3,822,471 −1.3% of holding | |
| Ferrari Mauro | Director | Sell 10b5-1 | 7,530 | $70.00 | $527.1K | 69,053 −9.8% of holding | |
| Anzalone Christopher Richard 2 fills | Chief Executive Officer | Sell 10b5-1 | 12,586 | $68.44 | $861.3K | 3,808,500 −0.3% of holding | |
| Anzalone Christopher Richard 3 fills | Chief Executive Officer | Sell 10b5-1 | 13,445 | $67.66 | $909.7K | 3,827,978 −0.4% of holding | |
| Vakiener Victoria 3 fills | Director | Sell 10b5-1 | 10,040 | $67.68 | $679.5K | 42,964 −18.9% of holding | |
| OLUKOTUN ADEOYE Y 3 fills | Director | Sell 10b5-1 | 10,000 | $67.66 | $676.6K | 40,510 −19.8% of holding | |
| Waddill William D. 3 fills | Director | Sell 10b5-1 | 8,367 | $67.65 | $566.0K | 62,514 −11.8% of holding | |
| Anzalone Christopher Richard 4 fills | Chief Executive Officer | Sell | 85,000 | $64.04 | $5.4M | 3,870,670 −2.1% of holding | |
| Anzalone Christopher Richard 9 fills | Chief Executive Officer | Sell | 54,298 | $62.58 | $3.4M | 3,962,839 −1.4% of holding | |
| Anzalone Christopher Richard 3 fills | Chief Executive Officer | Sell | 130,000 | $68.85 | $9.0M | 4,000,723 −3.1% of holding | |
| PERRY MICHAEL S | Director | Sell | 16,250 | $61.03 | $991.7K | 115,240 −12.4% of holding | |
| Ferrari Mauro | Director | Sell | 8,750 | $56.39 | $493.4K | 68,764 −11.3% of holding | |
| Hamilton James C | Chief Medical Officer | Sell 10b5-1 | 20,000 | $35.00 | $700.0K | 212,122 −8.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.